PROCEPT BioRobotics Shareholders Back Board, Pay and Auditor

PROCEPT BioRobotics shareholders approved all board director nominees, ratified PricewaterhouseCoopers as auditor, and supported executive compensation at the June 9, 2026 annual meeting. While analysts maintain a 'Buy' rating with a $34 target, TipRanks' AI analyst rates PRCT as 'Neutral' due to ongoing losses and negative cash flow, despite strong revenue growth and constructive guidance toward profitability.

Introducing TipRanks MCP for Agents

Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

An announcement from PROCEPT BioRobotics ( (PRCT) ) is now available.

At PROCEPT BioRobotics Corporation’s annual meeting of stockholders held on June 9, 2026, all director nominees listed in the company’s April 22, 2026 proxy statement were elected to the board to serve until the 2029 annual meeting or until their successors are chosen. Antal Desai, Mary Garrett, and Frederic Moll, M.D., each received strong shareholder support, with Moll in particular drawing notably high votes in favor relative to withheld votes.

Shareholders also ratified the selection of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, signaling broad shareholder backing for current leadership, governance, and compensation practices.

The most recent analyst rating on (PRCT) stock is a Buy
with a $34.00 price target.
To see the full list of analyst forecasts on PROCEPT BioRobotics stock,
see the PRCT Stock Forecast page.

Spark’s Take on PRCT Stock

According to Spark, TipRanks’ AI Analyst, PRCT is a Neutral.

The score is held back primarily by ongoing losses and persistent negative free cash flow despite strong revenue growth and improving gross margins. Technicals also remain weak with the stock below key moving averages and negative MACD. Offsetting these, the earnings call was constructive with reaffirmed high-growth guidance and an explicit path toward positive adjusted EBITDA by Q4, though near-term execution and cost pressures remain key risks.

To see Spark’s full report on PRCT stock,
click here.

More about PROCEPT BioRobotics

PROCEPT BioRobotics Corporation operates in the medical technology industry, focusing on surgical robotics and related systems for urologic procedures. The company’s primary products are designed to improve treatment outcomes for conditions such as benign prostatic hyperplasia, targeting hospitals, surgical centers, and urology practices as key customers.

Average Trading Volume: 1,420,017

Technical Sentiment Signal: Sell

Current Market Cap: $1.64B

Learn more about PRCT stock on TipRanks’ Stock Analysis page.